DK3532064T3 - Kombinationsbehandlinger omfattende imidazopyrazinoner til behandlingen af psykiatriske og/eller kognitive lidelser - Google Patents
Kombinationsbehandlinger omfattende imidazopyrazinoner til behandlingen af psykiatriske og/eller kognitive lidelser Download PDFInfo
- Publication number
- DK3532064T3 DK3532064T3 DK17791080.9T DK17791080T DK3532064T3 DK 3532064 T3 DK3532064 T3 DK 3532064T3 DK 17791080 T DK17791080 T DK 17791080T DK 3532064 T3 DK3532064 T3 DK 3532064T3
- Authority
- DK
- Denmark
- Prior art keywords
- imidazopyrazinones
- psychiatric
- treatment
- cognitive disorders
- combination treatments
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA201600659 | 2016-10-28 | ||
PCT/EP2017/077497 WO2018078038A1 (en) | 2016-10-28 | 2017-10-26 | Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3532064T3 true DK3532064T3 (da) | 2020-08-24 |
Family
ID=60186299
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK17791080.9T DK3532064T3 (da) | 2016-10-28 | 2017-10-26 | Kombinationsbehandlinger omfattende imidazopyrazinoner til behandlingen af psykiatriske og/eller kognitive lidelser |
Country Status (29)
Country | Link |
---|---|
US (1) | US10905688B2 (da) |
EP (1) | EP3532064B1 (da) |
JP (1) | JP2019536762A (da) |
KR (1) | KR20190075068A (da) |
CN (1) | CN109803658A (da) |
AR (1) | AR109991A1 (da) |
AU (1) | AU2017350473A1 (da) |
BR (1) | BR112018013247A2 (da) |
CA (1) | CA3041607A1 (da) |
CL (1) | CL2019001091A1 (da) |
CO (1) | CO2019002909A2 (da) |
CY (1) | CY1123396T1 (da) |
DK (1) | DK3532064T3 (da) |
ES (1) | ES2816005T3 (da) |
HR (1) | HRP20201326T1 (da) |
HU (1) | HUE050403T2 (da) |
IL (1) | IL265635A (da) |
LT (1) | LT3532064T (da) |
MA (1) | MA46611B1 (da) |
ME (1) | ME03821B (da) |
MX (1) | MX2019004763A (da) |
PL (1) | PL3532064T3 (da) |
PT (1) | PT3532064T (da) |
RS (1) | RS60716B1 (da) |
RU (1) | RU2019109039A (da) |
SG (1) | SG11201903770UA (da) |
SI (1) | SI3532064T1 (da) |
WO (1) | WO2018078038A1 (da) |
ZA (1) | ZA201902091B (da) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201629064A (zh) | 2014-10-10 | 2016-08-16 | H 朗德貝克公司 | 作爲pde1抑制劑之三唑並吡酮 |
JO3627B1 (ar) | 2015-04-30 | 2020-08-27 | H Lundbeck As | إيميدازو بيرازينونات على هيئة مثبطات pde1 |
TWI729109B (zh) | 2016-04-12 | 2021-06-01 | 丹麥商H 朗德貝克公司 | 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮 |
US10633382B2 (en) | 2016-10-18 | 2020-04-28 | H. Lundbeck A/S | Imidazopyrazinones, pyrazolopyrimidinones and pyrazolopyridinones as PDE1 inhibitors |
PL3532064T3 (pl) | 2016-10-28 | 2020-11-16 | H. Lundbeck A/S | Terapie skojarzone obejmujące imidazopirazynony do leczenia zaburzeń psychiatrycznych i/lub poznawczych |
MA46621A (fr) | 2016-10-28 | 2021-06-02 | H Lundbeck As | Traitements combinés comprenant l'administration d'imidazopyrazinones |
WO2019151274A1 (ja) | 2018-02-01 | 2019-08-08 | 日本たばこ産業株式会社 | 含窒素複素環アミド化合物及びその医薬用途 |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB973361A (en) | 1960-05-11 | 1964-10-28 | Ciba Ltd | Pyrazolo-pyrimidines and process for their manufacture |
DE19709877A1 (de) | 1997-03-11 | 1998-09-17 | Bayer Ag | 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate |
MY144532A (en) | 2001-08-20 | 2011-09-30 | Lundbeck & Co As H | Novel method for down-regulation of amyloid |
DE10238724A1 (de) | 2002-08-23 | 2004-03-04 | Bayer Ag | Alkyl-substituierte Pyrazolpyrimidine |
DE10238723A1 (de) | 2002-08-23 | 2004-03-11 | Bayer Ag | Phenyl-substituierte Pyrazolyprimidine |
DE10238722A1 (de) | 2002-08-23 | 2004-03-11 | Bayer Ag | Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse |
JP2006525966A (ja) | 2003-05-09 | 2006-11-16 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | 6−シクリルメチル−および6−アルキルメチル置換ピラゾロピリミジン類 |
WO2006068978A2 (en) | 2004-12-21 | 2006-06-29 | Takeda Pharmaceutial Company Limited | Dipeptidyl peptidase inhibitors |
US20080194592A1 (en) | 2005-08-23 | 2008-08-14 | Intra-Cellular Therapies, Inc. | Organic Compounds |
US8012936B2 (en) | 2006-03-29 | 2011-09-06 | New York University | Tau fragments for immunotherapy |
JP5837278B2 (ja) | 2006-12-05 | 2015-12-24 | イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. | 新規使用 |
NZ580904A (en) | 2007-05-11 | 2012-02-24 | Pfizer | Amino-heterocyclic compounds for inhibiting pde9 |
US20090143391A1 (en) | 2007-11-30 | 2009-06-04 | Norbert Hofgen | Aryl and heteroaryl fused imidazo [1,5-a] pyrazines as inhibitors of phosphodiesterase 10 |
UA105362C2 (en) | 2008-04-02 | 2014-05-12 | Бьорингер Ингельхайм Интернациональ Гмбх | 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators |
WO2010026214A1 (en) | 2008-09-08 | 2010-03-11 | Boehringer Ingelheim International Gmbh | Pyrazolopyrimidines and their use for the treatment of cns disorders |
JP5813511B2 (ja) | 2008-12-06 | 2015-11-17 | イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. | 有機化合物 |
TWI404721B (zh) | 2009-01-26 | 2013-08-11 | Pfizer | 胺基-雜環化合物 |
CA3120504A1 (en) | 2009-06-10 | 2010-12-16 | New York University | Immunological targeting of pathological tau proteins |
US9434730B2 (en) | 2010-05-31 | 2016-09-06 | Intra-Cellular Therapies, Inc. | PDE1 inhibitor compounds |
CN103068848B (zh) | 2010-08-12 | 2015-11-25 | 伊莱利利公司 | 抗N3pGlu淀粉样蛋白BETA肽抗体及其用途 |
EP2619208B1 (en) | 2010-09-20 | 2016-11-09 | Ironwood Pharmaceuticals, Inc. | Imidazotriazinone compounds |
WO2012040048A2 (en) | 2010-09-21 | 2012-03-29 | Schering Corporation | Triazolopyrazinones as p2x7 receptor antagonists |
JO3089B1 (ar) | 2010-11-19 | 2017-03-15 | H Lundbeck As | مشتقات ايميدازول كمثبطات لانزيمات pde10a |
AR085840A1 (es) * | 2011-04-05 | 2013-10-30 | Otsuka Pharma Co Ltd | Medicamento que contiene un compuesto que es 7-[4-(4-benzo[b]tiofen-4-il-piperazin-1-il)butoxi]-1h-quinolin-2-ona |
WO2012136552A1 (en) | 2011-04-08 | 2012-10-11 | H. Lundbeck A/S | ANTIBODIES SPECIFIC TO PYROGLUTAMATED Αβ |
JP6051210B2 (ja) | 2011-06-10 | 2016-12-27 | イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. | 有機化合物 |
MA37958B1 (fr) * | 2011-10-10 | 2018-10-31 | H Lundbeck As | Pde9i ayant un squelette imidazo pyrazinone |
EP3178820B1 (en) | 2012-01-26 | 2017-12-20 | H. Lundbeck A/S | Pde9- inhibitors with imidazo triazinone backbone |
MX357320B (es) | 2012-06-18 | 2018-07-04 | Dart Neuroscience Cayman Ltd | Compuestos de la azolopirimidina-5-(6h)-ona de piridina sustituida. |
US9073936B2 (en) | 2013-03-15 | 2015-07-07 | Intra-Cellular Therapies, Inc. | Organic compounds |
JP5783297B2 (ja) | 2013-08-06 | 2015-09-24 | 株式会社デンソー | 力学量センサ |
UA117695C2 (uk) | 2014-02-19 | 2018-09-10 | Х. Луннбек А/С | 2-аміно-3,5,5-трифтор-3,4,5,6-тетрагідропіридини як інгібітори bace1 для лікування хвороби альцгеймера |
JP5797815B1 (ja) | 2014-06-27 | 2015-10-21 | 細田建設株式会社 | 後施工アンカー及びその施工方法 |
WO2016042775A1 (en) | 2014-09-18 | 2016-03-24 | Sunovion Pharmaceuticals Inc. | Tricyclic derivative |
US20160083400A1 (en) | 2014-09-18 | 2016-03-24 | Sunovion Pharmaceuticals Inc. | Tricyclic guanidine derivative |
US20160083391A1 (en) | 2014-09-18 | 2016-03-24 | Sunovion Pharmaceuticals Inc. | Tricyclic piperazine derivative |
TW201629064A (zh) * | 2014-10-10 | 2016-08-16 | H 朗德貝克公司 | 作爲pde1抑制劑之三唑並吡酮 |
JO3458B1 (ar) | 2014-11-10 | 2020-07-05 | H Lundbeck As | 2- أمينو-6- (دايفلوروميثيل) – 5، 5- ديفلورو-6-فينيل-3،4، 5، 6-تيتراهيدروبيريدين كمثبطات bace1 |
CR20170187A (es) | 2014-11-10 | 2018-02-01 | H Lundbeck As | 2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1 para el tratamiento de la enfermedad de Alzheimer |
MA40941A (fr) | 2014-11-10 | 2017-09-19 | H Lundbeck As | 2-amino-5,5-difluoro-6-(fluorométhyl)-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1 |
US20180044343A1 (en) | 2015-03-16 | 2018-02-15 | Sumitomo Dainippon Pharma Co., Ltd. | Bicyclic imidazolo derivative |
US20160311831A1 (en) | 2015-04-22 | 2016-10-27 | H. Lundbeck A/S | Imidazotriazinones as PDE1 Inhibitors |
JO3627B1 (ar) | 2015-04-30 | 2020-08-27 | H Lundbeck As | إيميدازو بيرازينونات على هيئة مثبطات pde1 |
JO3711B1 (ar) | 2015-07-13 | 2021-01-31 | H Lundbeck As | أجسام مضادة محددة لبروتين تاو وطرق استعمالها |
EP3334720A1 (en) | 2015-08-12 | 2018-06-20 | H. Lundbeck A/S | 2-amino-3-fluoro-3-(fluoromethyl)-6-methyl-6-phenyl-3,4,5,6-tetrahydropyridins as bace1 inhibitors |
CN105254635A (zh) * | 2015-10-30 | 2016-01-20 | 中国药科大学 | 一类咪唑并吡嗪类化合物及其药物组合物和用途 |
TWI609870B (zh) | 2016-02-12 | 2018-01-01 | 美國禮來大藥廠 | Pde1抑制劑 |
TWI729109B (zh) | 2016-04-12 | 2021-06-01 | 丹麥商H 朗德貝克公司 | 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮 |
JP2018076285A (ja) | 2016-09-14 | 2018-05-17 | 大日本住友製薬株式会社 | 二環性イミダゾロ誘導体を含む医薬 |
US10633382B2 (en) | 2016-10-18 | 2020-04-28 | H. Lundbeck A/S | Imidazopyrazinones, pyrazolopyrimidinones and pyrazolopyridinones as PDE1 inhibitors |
MA46621A (fr) | 2016-10-28 | 2021-06-02 | H Lundbeck As | Traitements combinés comprenant l'administration d'imidazopyrazinones |
PL3532064T3 (pl) | 2016-10-28 | 2020-11-16 | H. Lundbeck A/S | Terapie skojarzone obejmujące imidazopirazynony do leczenia zaburzeń psychiatrycznych i/lub poznawczych |
-
2017
- 2017-10-26 PL PL17791080T patent/PL3532064T3/pl unknown
- 2017-10-26 LT LTEP17791080.9T patent/LT3532064T/lt unknown
- 2017-10-26 RU RU2019109039A patent/RU2019109039A/ru not_active Application Discontinuation
- 2017-10-26 AU AU2017350473A patent/AU2017350473A1/en not_active Abandoned
- 2017-10-26 CN CN201780063182.9A patent/CN109803658A/zh active Pending
- 2017-10-26 MA MA46611A patent/MA46611B1/fr unknown
- 2017-10-26 US US16/345,136 patent/US10905688B2/en active Active
- 2017-10-26 BR BR112018013247A patent/BR112018013247A2/pt not_active Application Discontinuation
- 2017-10-26 DK DK17791080.9T patent/DK3532064T3/da active
- 2017-10-26 MX MX2019004763A patent/MX2019004763A/es unknown
- 2017-10-26 ES ES17791080T patent/ES2816005T3/es active Active
- 2017-10-26 RS RS20200975A patent/RS60716B1/sr unknown
- 2017-10-26 JP JP2019522523A patent/JP2019536762A/ja active Pending
- 2017-10-26 CA CA3041607A patent/CA3041607A1/en not_active Abandoned
- 2017-10-26 SG SG11201903770UA patent/SG11201903770UA/en unknown
- 2017-10-26 PT PT177910809T patent/PT3532064T/pt unknown
- 2017-10-26 KR KR1020197011509A patent/KR20190075068A/ko not_active Application Discontinuation
- 2017-10-26 SI SI201730388T patent/SI3532064T1/sl unknown
- 2017-10-26 EP EP17791080.9A patent/EP3532064B1/en active Active
- 2017-10-26 WO PCT/EP2017/077497 patent/WO2018078038A1/en unknown
- 2017-10-26 ME MEP-2020-170A patent/ME03821B/me unknown
- 2017-10-26 HU HUE17791080A patent/HUE050403T2/hu unknown
- 2017-10-27 AR ARP170102997A patent/AR109991A1/es unknown
-
2019
- 2019-03-26 IL IL265635A patent/IL265635A/en unknown
- 2019-03-27 CO CONC2019/0002909A patent/CO2019002909A2/es unknown
- 2019-04-03 ZA ZA2019/02091A patent/ZA201902091B/en unknown
- 2019-04-22 CL CL2019001091A patent/CL2019001091A1/es unknown
-
2020
- 2020-08-24 CY CY20201100788T patent/CY1123396T1/el unknown
- 2020-08-25 HR HRP20201326TT patent/HRP20201326T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
BR112018013247A2 (pt) | 2018-12-04 |
ES2816005T3 (es) | 2021-03-31 |
CY1123396T1 (el) | 2021-12-31 |
RU2019109039A3 (da) | 2021-01-29 |
IL265635A (en) | 2019-05-30 |
RU2019109039A (ru) | 2020-11-30 |
CA3041607A1 (en) | 2018-05-03 |
PT3532064T (pt) | 2020-09-03 |
WO2018078038A1 (en) | 2018-05-03 |
HUE050403T2 (hu) | 2020-12-28 |
RS60716B1 (sr) | 2020-09-30 |
CN109803658A (zh) | 2019-05-24 |
SI3532064T1 (sl) | 2020-10-30 |
EP3532064A1 (en) | 2019-09-04 |
KR20190075068A (ko) | 2019-06-28 |
PL3532064T3 (pl) | 2020-11-16 |
AR109991A1 (es) | 2019-02-13 |
AU2017350473A1 (en) | 2019-04-18 |
CL2019001091A1 (es) | 2019-07-05 |
EP3532064B1 (en) | 2020-07-29 |
SG11201903770UA (en) | 2019-05-30 |
MX2019004763A (es) | 2019-07-01 |
US10905688B2 (en) | 2021-02-02 |
JP2019536762A (ja) | 2019-12-19 |
ME03821B (me) | 2021-04-20 |
HRP20201326T1 (hr) | 2020-11-27 |
LT3532064T (lt) | 2020-09-25 |
CO2019002909A2 (es) | 2019-06-19 |
US20190282571A1 (en) | 2019-09-19 |
MA46611A (fr) | 2019-09-04 |
ZA201902091B (en) | 2020-10-28 |
MA46611B1 (fr) | 2020-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3600281T3 (da) | Kombinationsbehandling til behandling eller forebyggelse af tumorer | |
DK3570844T3 (da) | Azolopyrimidin til behandlingen af kræftrelaterede lidelser | |
DK3673080T3 (da) | Antisense-oligomerer til behandling af lidelser og sygdomme | |
DK3532064T3 (da) | Kombinationsbehandlinger omfattende imidazopyrazinoner til behandlingen af psykiatriske og/eller kognitive lidelser | |
DK3402888T3 (da) | Middel og fremgangsmåder til behandling af hbv | |
DK3407889T3 (da) | Organiske forbindelser og deres anvendelse til behandling og forebyggelse af lidelser i centralnervesystemet | |
DK3185876T3 (da) | Sammensætninger og fremgangsmåder til behandling af neurologiske lidelser | |
DK3285803T3 (da) | Fremgangsmåder til behandling eller forebyggelse af migrænehovedpine | |
DK3277815T3 (da) | Oligonukleotidforbindelser til behandling af præeklampsi og andre angiogene lidelser | |
DK3402499T3 (da) | Sammensætninger og fremgangsmåder til behandlingen af type 1 diabetes | |
DK3362066T3 (da) | Kombinationsterapi til behandling af maligniteter | |
DK3481846T3 (da) | 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande | |
DK3288577T3 (da) | Adiponectin-peptidomimetika til behandling af øjenlidelser | |
DK3558280T3 (da) | Forebyggelse og behandling af migræne | |
IL290754A (en) | Use of pyridofidine to treat anxiety and depression | |
DK3242947T3 (da) | Genterapi og elektroporese til behandling af maligniteter | |
DK3390367T3 (da) | Fremgangsmåde til forebyggelse og/eller behandling af aldersrelateret kognitiv funktionsnedsættelse og neuroinflammation | |
DK3439661T3 (da) | Fremgangsmåder til behandling af øjenlidelser | |
DK3191103T3 (da) | Sammensætninger og fremgangsmåder til behandling af præcancerøse hudlæsioner | |
DK3261661T3 (da) | Menotropin til behandling af infertilitet | |
DK3416580T3 (da) | Enhed til bestråling af huden | |
DK3478679T3 (da) | 5,7-dihydro-pyrrolo-pyridin-derivater til behandling af neurologiske og neurodegenerative sygdomme | |
DK3522873T3 (da) | Sammensætninger og fremgangsmåder til behandlingen af xerostomi | |
DK3529234T3 (da) | Forbindelser, fremgangsmåde til opnåelse af forbindelserne, farmaceutisk sammensætning, anvendelse af forbindelserne og fremgangsmåde til behandling af psykiatriske lidelser og/eller søvnforstyrrelser | |
DK3493812T3 (da) | Kombinationer af imetelstat og venetoclax til behandling af akut myeloid leukæmi |